What We Do
ForSight VISION5 is focused on developing non-invasive products that replace eye drops and provide sustained therapy for major eye diseases including glaucoma, dry eye, and allergy.
ForSight VISION5’s lead product candidate is the Bimatoprost Ring, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive their medication. The ring is an ocular insert that rests under the eyelids and is formulated with a drug which releases onto the eye. This drug, bimatoprost, has previously been approved for intraocular pressure reduction in eye drop formulation. The Bimatoprost Ring is currently in its second multi-center, randomized, active controlled Phase 2 clinical study in the U.S.A. to assess the insert over the course of six months. A larger Phase 2 randomized, controlled trial has been completed. ForSight VISION5 is also developing non-invasive, sustained release products for other major anterior segment eye diseases.